{"entity":{"id":"rise-therapeutics","kind":"company","name":"Rise Therapeutics","aka":["Rise Therapeutics, LLC","Rise Therapeutics LLC"],"tldr":"Rise Therapeutics develops oral immune treatments. Its cancer medicine, R-5780, is a pill meant to help checkpoint immunotherapy work in tumours that have not responded to it, and it is in an early trial.","summary":"Rise Therapeutics develops oral immunotherapies with its own oral delivery platform and in-house GMP manufacturing, for autoimmune disease and cancer. Its oncology product R-5780 is designed to enhance immune checkpoint inhibitor activity; the NIH RePORTER abstract describes it as based on secreted antigen A (SagA), an enzyme from Enterococcus faecium that engages microbiome-associated immune pathways. R-5780 is in a phase 1 trial with PD-1 inhibitors in solid tumours (NCT06398418). In fiscal year 2026 NCI awarded the company USD 740,140 under SBIR award 1R44CA306440-01A1 for clinical validation of R-5780.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://risetherapeutics.com/"},{"label":"Rise Therapeutics: pipeline","url":"https://risetherapeutics.com/pipeline/"},{"label":"NIH RePORTER: SBIR award 1R44CA306440-01A1","url":"https://reporter.nih.gov/project-details/11399439"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["microbiome-modulation-io"],"targets":[],"drugs":["r-5780"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The website also lists autoimmune programmes, not recorded here. Read on risetherapeutics.com, ClinicalTrials.gov and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"Rockville, MD","country":"US","companyType":"biotech","website":"https://risetherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":740140,"source":"https://reporter.nih.gov/project-details/11399439","note":"NCI SBIR award (R44) 1R44CA306440-01A1: Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors"}]},"route":"/companies/rise-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/"}],"drug":[{"id":"r-5780","kind":"drug","name":"R-5780","route":"/drugs/r-5780/"}]}}